US bill aims to provide exclusivity, other incentives for antibiotic makers

Makers of antibiotics to treat the nastiest, most drug-resistant bugs could gain an additional five years of data exclusivity protection and be granted fast-track status and six-month priority reviews by the US FDA if certain members of the US House of Representatives have their way.